Endocrine Abnormalities in Gordon Syndrome Associated with CUL3 Mutation: A Case Study
By
Mahsa Fatahichegeni
Mohammad Amin Ansarian
Hongjun Lv
Jiao Fu
July 20, 2026
Clinical Scorecard: Endocrine Abnormalities in Gordon Syndrome Associated with CUL3 Mutation: A Case Study
At a Glance
Category Detail
Condition Gordon syndrome (Pseudohypoaldosteronism type II) Key Mechanisms CUL3 mutations lead to impaired renal potassium excretion and hormonal dysregulation. Target Population Patients with CUL3-related Gordon syndrome. Care Setting Clinical evaluation and management of endocrine abnormalities.
Key Highlights
CUL3 mutations produce the most severe phenotype of Gordon syndrome. Endocrine manifestations include insulin resistance and primary testicular dysfunction. Thiazide diuretic therapy normalized blood pressure and serum potassium. Improvements in metabolic and hormonal abnormalities were reversible upon treatment discontinuation. Comprehensive endocrine evaluation is important in affected patients. Guideline-Based Recommendations
Diagnosis
Genetic analysis for CUL3 mutations in patients with hyperkalemia and hypertension. Management
Thiazide diuretics for blood pressure and potassium management. Monitoring & Follow-up
Regular monitoring of serum electrolytes and hormonal levels. Risks
Potential for chronic electrolyte imbalance leading to broader metabolic dysregulation. Patient & Prescribing Data
Young adults with CUL3-related Gordon syndrome.
Sustained thiazide therapy is necessary to maintain metabolic and hormonal improvements.
Clinical Best Practices
Conduct thorough endocrine evaluations in patients with Gordon syndrome. Consider genetic counseling for families with a history of CUL3 mutations. Related Resources & Content
